Reviewing PolyPid (NASDAQ:PYPD) and Roche (OTCMKTS:RHHBY)

PolyPid (NASDAQ:PYPD) and Roche (OTCMKTS:RHHBY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for PolyPid and Roche, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1	0	3	0	2.50
Roche	1	5	5	0	2.36

PolyPid presently has a consensus price target of $11.33, suggesting a potential upside of 122.22%. Roche has a consensus price target of $60.00, suggesting a potential upside of 3.27%. Given PolyPid’s stronger consensus rating and higher possible upside, research analysts plainly believe PolyPid is more favorable than Roche.

Profitability

This table compares PolyPid and Roche’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Roche	N/A	N/A	N/A

Earnings & Valuation

This table compares PolyPid and Roche”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17 million	($1.48)	-3.45
Roche	$76.45 billion	4.84	$15.55 billion	N/A	N/A

Roche has higher revenue and earnings than PolyPid.

Volatility and Risk

PolyPid has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Roche has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Institutional and Insider Ownership

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.